Gold prices steady ahead of Fed decision; weekly weakness noted
Y-mAbs Therapeutics, Inc. (NASDAQ:YMAB) recently disclosed that Michael J. Rossi, the company’s President and CEO, sold 3,917 shares of common stock on March 7, 2025. The shares were sold at a price of $5.20 each, amounting to a total transaction value of $20,368. The transaction comes as the stock trades significantly below its 52-week high of $17.78, having declined nearly 70% over the past year. According to InvestingPro analysis, the stock appears undervalued at current levels, with analysts setting price targets ranging from $7 to $26. This sale was a nondiscretionary transaction to cover tax liabilities associated with the vesting and settlement of restricted stock units. Following this transaction, Rossi holds 137,083 shares in the company. Despite recent price weakness, InvestingPro data shows the company maintains a strong financial position with a current ratio of 4.16 and more cash than debt on its balance sheet. For deeper insights into Y-mAbs’ financial health and growth prospects, investors can access the comprehensive Pro Research Report, available exclusively on InvestingPro.
In other recent news, Y-mAbs Therapeutics has announced its fiscal year 2024 revenue of $87.7 million, aligning with market expectations. However, the company’s guidance for 2025 suggests revenues may fall between $75 million and $90 million, prompting several analysts to adjust their price targets. Jones Trading lowered its target from $23 to $18 while maintaining a Buy rating, citing the revised guidance as a reason for the adjustment. Morgan Stanley (NYSE:MS) also reduced its target from $11 to $7, maintaining an Underweight rating due to challenges faced by the company’s product, Danyelza. Meanwhile, Cantor Fitzgerald adjusted its price target to $19 from $20, retaining an Overweight rating, and BofA Securities set a new target of $12, maintaining a Neutral stance. Additionally, Y-mAbs Therapeutics entered into an Equity Distribution Agreement with Oppenheimer & Co. Inc. for potential offerings of up to $35 million in common stock. This agreement provides the company with flexibility in financing its operations. The company’s strategic realignment and updates on its GD2-SADA platform remain focal points for analysts and investors.
This article was generated with the support of AI and reviewed by an editor. For more information see our T&C.